Answers are grounded in this paper and cite their sources.
OBJECTIVES: We evaluated urinary β2-microglobulin (U-β2M) as a prognostic and treatment-associated marker in anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis (MDA5-DM) with interstitial lung disease (ILD). METHODS: We retrospectively identified 68 patients with MDA5-DM admitted between January 2004 and March 2023. After excluding five patients with confirmed or indeterminate outcomes unrelated to MDA5-DM, 63 patients were included (20 deaths, 43 survivors); baseline U-β2M was available in 52 patients (16 deaths, 36 survivors). Pre-treatment levels, longitudinal changes, and correlations with serum ferritin and anti-MDA5 antibody titres were evaluated. RESULTS: At admission, U-β2M levels were significantly higher in the deceased group (p = 0.011). U-β2M predicted mortality (area under the curve 0.72), comparable to serum ferritin and anti-MDA5 antibody titres (0.68 and 0.69), and significantly higher than serum Krebs von den Lungen-6 (KL-6) (0.50; p = 0.0394). U-β2M correlated with anti-MDA5 antibody titres (p < 0.0001) and serum ferritin (p < 0.0001). Post-treatment U-β2M decreased in survivors (p = 0.009) but increased in deceased patients (p = 0.009). Serum ferritin did not change significantly (p = 0.086 and p = 0.782, respectively); KL-6 did not change significantly in survivors (p = 0.059) but increased in the deceased group (p < 0.0001). CONCLUSION: U-β2M is a promising, non-invasive prognostic and treatment-associated marker for MDA5-DM with ILD, showing more pronounced longitudinal change than serum ferritin and KL-6. However, given the retrospective, single-center design of this study, prospective validation in larger cohorts is warranted.
No takes yet. Share an insight, caveat, or question.
Nakamura et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: